MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immunohistochemistry or IHC

Often used to diagnose cancer, Immunohistochemistry or IHC is a process by which antibodies are detected in tissue samples by use of a specific antigen or antigens. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue (also see “Serum Marker/Blood Test“).

HEG1, BAP1, and MTAP Are Useful in Cytologic Diagnosis of Malignant Mesothelioma With Effusion

Diagnostic Cytopathology 2020 May 22 [Link] Kenzo Hiroshima, Di Wu, Shinji Hamakawa, Shingo Tsuruoka, Daisuke Ozaki, Hideki Orikasa, Mizue Hasegawa, Eitetsu Koh, Yasuo Sekine, Yoko Yonemori, Kazuki Nabeshima, Shoutaro Tsuji, Yohei Miyagi, Kohzoh Imai Abstract Background: The specificity and sensitivity of HEG1 for malignant mesothelioma (MM) is high. The use of BAP1/MTAP immunohistochemistry (IHC) is […]

June 1, 2020

effusion cytology, Full Archive, Immunohistochemistry or IHC, Pleural, Pleural Effusion
Comments Off on HEG1, BAP1, and MTAP Are Useful in Cytologic Diagnosis of Malignant Mesothelioma With Effusion

Gender Differences in Molecular-Guided Therapy Recommendations for Metastatic Malignant Mesothelioma

Thoracic Cancer 2020 May 21 [Link] Hossein Taghizadeh, Sabine Zöchbauer-Müller, Robert M Mader, Leonhard Müllauer, Thomas Klikovits, Thomas Bachleitner-Hofmann, Mir A Hoda, Gerald W Prager Abstract Background: Malignant mesothelioma is an aggressive cancer and has a poor prognosis. Here, we analyzed the feasibility, molecular and gender aspects of targeted therapy recommendations for malignant mesothelioma based […]

May 29, 2020

Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on Gender Differences in Molecular-Guided Therapy Recommendations for Metastatic Malignant Mesothelioma

Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Oncology Letters 2020 June [Link] Guozun Zhang, Dong-Liang Yang, Guoqi Zheng, Yufei Liang Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer strongly associated with asbestos exposure and characterised by poor prognosis. The aim of the present study was to elucidate the prognostic and predictive value of CD146 and survivin expression in MPeM. Diagnostic biopsies […]

May 22, 2020

Chemotherapy, Full Archive, Immunohistochemistry or IHC, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma)
Comments Off on Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.

International Immunopharmacology 2020 April 24 [Link] Zhang F, Gong W Abstract OBJECTIVE:Programmed death ligand 1 (PD-L1) has been reported to be connected to prognosis in individuals with malignant pleural mesothelioma (MPM), although there is no consensus based on data from previous studies. Accordingly, this quantitative meta-analysis investigated prognostic and clinicopathological utility of PD-L1 in patients […]

May 11, 2020

Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.

Defense and protection mechanisms in lung exposed to asbestiform fiber: the role of macrophage migration inhibitory factor and heme oxygenase-1.

European Journal of Histochemistry 2020 April 16 [Link] Loreto C, Caltabiano R, Graziano ACE, Castorina S, Lombardo C, Filetti V, Vitale E, Rapisarda G, Cardile V, Ledda C, Rapisarda V. Abstract Fluoro-edenite (FE), an asbestiform fiber, is responsible for many respiratory pathologies: chronic obstructive diseases, pleural plaques, fibrosis, and malignant mesothelioma. Macrophage migration inhibitory factor […]

May 1, 2020

Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on Defense and protection mechanisms in lung exposed to asbestiform fiber: the role of macrophage migration inhibitory factor and heme oxygenase-1.

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

Journal of Thoracic Oncology 2020 March 9 [Link] Salle FG, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, […]

March 26, 2020

Biphasic or Mixed, Epithelioid, Full Archive, Immunohistochemistry or IHC, Pleural, Sarcomatoid
Comments Off on Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.

Cancers 2020 February 27 [Link] Trempolec N, Doix B, Degavre C, Brusa D, Bouzin C, Riant O, Feron O Abstract The potential of dendritic cell (DC)-based immunotherapy to treat cancer is, nowadays, well documented. Still, the clinical success of immune checkpoint inhibitors has dampened the interest in anticancer DC vaccination. For highly life-threatening tumors that […]

March 17, 2020

Full Archive, Immune-based Therapies, Immunohistochemistry or IHC, Peritoneal (Abdominal Mesothelioma), Photodynamic Therapy (PDT)
Comments Off on Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM) […]

March 12, 2020

Cisplatin (Platinol ®), Full Archive, Immunohistochemistry or IHC, Pemetrexed (Alimta), Pleural
Comments Off on A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.

Current Molecular Science 2020 February 20 [Link] Loreto C, Lombardo C, Caltabiano R, Ledda C, Hagnas M, Filetti V, Rapisarda V Abstract AIMS: The aim of this study was to investigate MacroH2A.1 immunoexpression in tissues of sheep exposed to FE. BACKGROUND: The correlation between asbestiform fibers, lung cancer, pleural mesothelioma and other lung diseases is […]

February 28, 2020

Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.

Differential diagnosis of malignant pleural mesothelioma on cytology: a gene expression panel versus BAP1 and p16 tests.

Journal of Molecular Diagnostics 2020 February 6 [Link] Bruno R, Alì G, Poma AM, Proietti A, Libener R, Mariani N, Niccoli C, Chella A, Ribechini A, Grosso F, Fontanini G Abstract Pleural effusions are among the first clinical manifestations of malignant pleural mesothelioma (MPM) and often constitute the only available material for diagnosis. Although an […]

February 18, 2020

Epithelioid, Full Archive, Immunohistochemistry or IHC, Pleural, Pleural Effusion
Comments Off on Differential diagnosis of malignant pleural mesothelioma on cytology: a gene expression panel versus BAP1 and p16 tests.